DA
ADMS

Denali Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

Denali Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-100
Closed -$2K – 310
2015
Q1 		$2K Hold
100
– – ﹤0.01% 235
2014
Q4 		$2K Hold
100
– – ﹤0.01% 213
2014
Q3 		$2K Buy
+100
New +$1.72K ﹤0.01% 197

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Denali Advisors's ADMS Position: Q2 2015 in Review

Denali Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q2 2015, closing a stake of 100 shares — an estimated $2K sold.

Denali Advisors first reported a position in ADMS in Q3 2014 and held it in 3 quarters. The position peaked at $2K in Q1 2015. 89 funds tracked by Wall St. Rank hold ADMS as of Q2 2015.

  • Denali Advisors reported no remaining Adamas Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Denali Advisors sold 100 Adamas Pharmaceuticals shares in Q2 2015, an estimated $2K.
  • Denali Advisors first reported a position in Adamas Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Denali Advisors's Adamas Pharmaceuticals position peaked at $2K in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2015.

Based on Denali Advisors's 13F filing for Q2 2015, filed 9 Jul 2015.